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Endometrial cancer is themost common gynecological malignancy
and the third most common cancer affecting women in the western
world. The majority of patients have disease conﬁned to the uterus
and have an excellent prognosis. However, a subgroup of patients
has advanced primary disease or recurrence following primary
treatment. The management of metastatic disease includes hormonal
therapy (progestational agents, aromatase inhibitors, tamoxifen) and
few cytotoxic agents (cisplatin or carboplatin, doxorubicin, ifosfamide
and paclitaxel). The median overall survival (OS) of patients affected
by metastatic endometrial carcinoma emerging from clinical trials is
about 12 months. The response rate (RR) for ﬁrst line of treatment
ranges from 31% to 81% and for second line of treatment from 15% to
42% with relatively short duration.
Trabectedin (Yondelis®: ET-743) is an intravenous anti-neoplastic
agent originally derived from the Caribbean marine tunicate Ecteinas-
cidia turbinata and now produced synthetically. Trabectedin has
shown variable levels of activity against several types of solid tumor
including soft tissue sarcoma (STS), ovarian cancer, breast, melano-
ma, non-small cell lung cancer (NSCLC), prostate and endometrial
cancer (McMeekin et al., 2009). Based on the results from a phase II
randomized, non-blind, multicentre trial and several other non-
comparative trials, the drug has currently been approved for the⁎ Corresponding author at: Largo Brambilla 3, 50139 Florence, Italy. Fax: +39 55
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chemotherapy (at least one cycle of anthracycline- and ifosfamide-
based chemotherapy) or uneligible for such treatment (Demetri et al.,
2009). The drug is especially active in leiomyosarcoma and liposarcoma,
the predominant histologic subtypes enrolled onto the registrative
study.
In this paper we report the case of a prolonged response to trabec-
tedin in a heavily pretreated woman with pulmonary metastases and
pleural effusion from endometrial carcinoma.Case report
On June 2002, a 60 year old woman (Caucasian) with no major
comorbidities, underwent total hysterectomy, bilateral salpingo-
oophorectomy and bilateral pelvic lymphadenectomy. The pathological
analysis reported adeno-squamous endometrial carcinoma inﬁltrating
two thirds inner of myometrium, pT1cN0M0, stage IC (TNM staging
5th edition). Subsequently the patient received adjuvant whole pelvic
external beam radiotherapy (50 GY TFD) and then began follow-up
without evidence of disease. The patient was referred to our institution
on January 2005 when pulmonary disease recurrence was assessed
by computer tomography (CT) and conﬁrmed by positron emission
tomography (PET). From January 2005 to September 2010 the patient
received two sequential hormonal treatments (megestrol acetate and
fulvestrant) and several lines of chemotherapy (carboplatin and Taxol,
non-pegylated liposomal doxorubicin, thalidomide, metronomic
cyclophosphamide and methotrexate, vinorelbine, mitoxantrone, 5-
FU). Overall best response (OBR) for each treatment, related toxicity
and sites of disease progression are detailed in Table 1. On September
2010 the patient developed performance status (ECOG PS) deteriora-
tion (PS: 1) with a symptomatic progression disease (cough, dyspnea,
asthenia, hemoptysis). Blood chemistry analysis showed anemia
(Hb 10 g/dl) and the echocardiogram revealedmild pericardial effusion.
The CT scan demonstrated appearance ofmild right pleural effusion and
conﬁrmed increase in the solid endobronchial lesion in the lower right
lobar bronchus and in the number and size of pulmonary lesions, as
shown in Fig. 1. Therefore, on 12th November 2010 the patient started
the 10th line of treatment with trabectedin (1.2 mg/mq 24-hour intra-
venous continuous infusion every 3 weeks). At each single administra-
tion the patient received standard steroid premedication. Consistent
with literature, the patient experienced elevated transaminases as
major side effect, which ranged G3 (Common Terminology Criteria for
Adverse Events version 4.0) after the third trabectedin administration
Table 1
Previous treatment: number of cycles, related toxicity, overall best response (OBR ) and sites of disease progression.
Type of treatment N° cycles OBR Related toxicity Sites of disease
progression
Reason for
withdrawal
Megestrol acetate
160 mg PO daily
Daily for 15 months SD Vascular G2
(deep vein thrombosis)
Lung PD
Fulvestrant IM
250 mg monthly
Monthly for 7 months SD Absent Lung PD
Carboplatin AUC 5 IV g1q21
+
Taxol 175 mg/mq IV g1q21
4 (Carboplatin only from the 2nd cycle
onward due to Taxol hypersensitivity)
PR Neutropenia G3
Alopecia G2
pericardial effusion G1
Sinus tachycardia G2
Lung PD
Myocet 75 mg/mq IV g1q21
+
G-CSF
4 SD Alopecia G2
Nausea G2
Lung PD
Thalidomide
200 mg PO daily g1q42
1 NE Peripheral neuropathy G3 NE Neurotoxicity
Endoxan 50 mg PO daily+methotrexate
2.5 mg PO twice a day, 2 days weekly
Weekly for 1 month PD Absent Lung PD
Vinorelbine 60 mg/mq
PO gg1,8q21
4 SD Neutropenia G2
Anemia G1
Sinus tachycardia G2
None Cardiotoxicity
Mitoxantrone 14 mg/mq
IV g1q21
3 SD Neutropenia G2 Lung PD
5-FU 400 mg/mq IV bolus g1q14
+
5FU 2100 mg/mq over
48 h IV continuous infusion g1q14
4 SD Absent Lung and pleura PD
NE: not evaluated; PD: progression disease; PR: partial response; SD: stable disease.
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steroid administration. Vomiting G1, diarrhea G1 and virus infection
G2 were also present infrequently as side effects. After 2 cycles of che-
motherapy, the patient achieved an evident clinical beneﬁt consisting
in the improvement of general condition (ECOGPS: 0) and the complete
disappearance of cough, dyspnea and hemoptysis. The CT scan per-
formed after the third cycle showed a dramatic partial response (PR),
which was further improved by three more cycles of chemotherapy as
shown in Fig. 2. No more toxicities were reported, so we established
to administer chemotherapy up to 8 cycles. Due to this prolonged and
impressive response to trabectedin we decided to assess mRNA expres-
sion levels of excision repair cross-complementing group 1 (ERCC1)
and breast cancer 1 (BRCA1), which could be involved in trabectedin
sensitivity as previously reported. Genetic tests were performed at the
laboratory of molecular biology at Universitary Hospital Germans Trial
I Pujol in Badalona (Barcelona). Due to the bad quality of samples,
they were able to amplify only ERCC1, with reported very low level
(1.99). This result is not consistent with literature data which suggest
that high ERCC1 expression levels are associated with major beneﬁt
from trabectedin. Trabectedinwas stopped after the 8th cycle, when pa-
tient showed recurrence of respiratory symptoms and the CT scan
revealed pulmonary disease progression (PD).Fig. 1. CT scan at baseline: this ﬁgure shows the twomajormeasurable lesions involving
the inferior right lung lobe, the major causing stenosis of inferior lobar bronchus.Discussion
The management of metastatic endometrial cancer is usually
palliative and includes, asmentioned above, hormonal therapies and cy-
totoxic drugs which can be used both in single-agent and multi-agent
regimens. Grade of differentiation, disease-free interval, location and
extent of extra-pelvicmetastases arewell recognized prognostic factors.
Our patient received several lines of treatment and achieved a
prolonged progression free survival (PFS) from ﬁrst and second line
hormonal agents whilst smaller beneﬁt from chemotherapy, which
was also associated with greater treatment related toxicity. For this
reason we carefully assessed the eligibility of the patient before
administering further chemotherapy with trabectedin.
As many other cytotoxic agents, the true mechanism of trabectedin
cytotoxicity remains unclear. We know that the drug binds to the
minor groove of DNA forming trabectedin-DNA adducts that bend
DNA towards the major groove. In this way trabectedin interferes
with the transcription-coupled nucleotide excision repair (TC-NER)
pathway, blocks the G2/M phase cell cycle and inhibits activated gene
transcription. The role of TC-NER is to recognize DNA lesions and to re-
move them from transcribed strands of expressed genes. ERCC1 is
a component of this repair system. Trabectedin disrupts this repairFig. 2. CT scan after the 6th trabectedin cycle: this ﬁgure shows the complete
disappearance of the anterior lesion and a major reduction in the posterior one, with
improvement also of bronchus compression.
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DNA damage through covalent bonds. Such lesions require homologous
recombination repair (HRR) pathway proteins to repair the damage.
Therefore solid tumor cells deﬁcient in one or more HRR proteins, like
BRCA1, are much more sensitive to trabectedin. Retrospective studies
suggest that the ERCC1 and the BRCA1 status may represent a compos-
ite signature that could be used to predict clinical response to trabecte-
din in patients affected by STS (Italiano et al., 2011; Schöffski et al.,
2011). In these patients high ERCC1 mRNA expression level is associat-
ed with improved although not statistically signiﬁcant RR, median PFS
and OS compared with low ERCC1 expression level. The same studies
generate the hypothesis that BRCA1 genotype and low expression
level correlate with major sensivity to trabectedin. In this sense our
data are not consistent with literature because in this case low ERCC1
mRNA expression level is associated with an impressive clinical re-
sponse. This is possibly due to different reasons. Firstly, we are evaluat-
ing a different disease (endometrial carcinoma) from the one analyzed
in the retrospective studies (STS) and so in our case trabectedin cyto-
toxicity could probably be induced by a different mechanism, even
TC-NER independent. This is consistent with the observation that in
our case trabectedin caused an impressive reduction in tumor burden,
while this drug is usually associatedwith low RR and prolonged periods
of stable disease in patient with STS. Secondly, we performed the quan-
tiﬁcation of the expression in the parafﬁn embedded sample of the pri-
mary tumor resected in 2002 and we do not know the genetic
characteristics of metastases, which could show high ERCC1 expression
levels instead. Assuming that ERCC1 expression levels are still low in the
sites of metastatic disease, we observe that in this situation trabectedin
shows similar behavior to other DNAdamaging agents used in the treat-
ment of different epithelial carcinoma, such as platinum compounds. In
fact, as noted in patients affected by NSCLC, tumor cells with low ERCC1
enzyme level may be more sensitive to platinum-based regimens since
they are less able to repair damaged DNA.In conclusion this unconventional therapy for endometrial cancer
conﬁrms the urgent need to redeﬁne and customize chemotherapy
according to clinical characteristics as well as histochemical, molecular
and genetic features.
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